Protagonist Therapeutics, Inc
ICOTYDE
plaque psoriasis
Resolved
97days ago
Phase 2 readout · Apr 1, 2026
What's at stake
Phase 2 trial results for ICOTYDE in plaque psoriasis are due Apr 1, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“Primary endpoint enrollment completion is expected in 2026 for: o The Phase 3, multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of icotrokinra for the treatment of biologic-naïve participant”